Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Netropsin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 2/20 | 0.71 |
| ▸ | ESR1 known ✓ | P03372 | 13/20 | 0.69 |
| ▸ | ESR2 known ✓ | Q92731 | 13/20 | 0.69 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.40 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.34 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | HRAS | P01112 | 14/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netropsin SCHEMBL4953090 | 0.99 | TOP1 (0.72) | TOP1KDM4EPOLBMAPTHIF1A | |
| Netropsin SCHEMBL10408939 | 0.99 | TOP1 (0.72) | TOP1KDM4EPOLBMAPTHIF1A | |
| SCHEMBL14267762 | 0.98 | TOP1 (0.74) | TOP1KDM4EPOLBMAPTHIF1A | |
| Netropsin SCHEMBL197747 | 0.98 | TOP1 (0.74) | TOP1KDM4EPOLBMAPTHIF1A | |
| SCHEMBL12348338 | 0.96 | TOP1 (0.70) | TOP1KDM4EPOLBMAPTHIF1A | |
| SCHEMBL12348157 | 0.92 | TOP1 (0.65) | TOP1KDM4EPOLBMAPTHIF1A | |
| SCHEMBL19288091 | 0.89 | TOP1 (0.62) | TOP1KDM4EPOLBMAPTHIF1A | |
| Netropsin SCHEMBL4955084 | 0.88 | TOP1 (0.56) | TOP1KDM4EPOLBMAPTHIF1A | |
| Netropsin SCHEMBL4284668 | 0.87 | TOP1 (0.60) | TOP1KDM4EPOLBMAPTHIF1A | |
| Hydrochloric Acid SCHEMBL10693314 | 0.86 | TOP1 (0.72) | TOP1KDM4EPOLBMAPTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | GREGG JOHN M H (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250099566-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | NATIONAL INSTITUTES OF HEALTH | 2025-03-27 | — | — | US | disclosed |
| US-20240173456-A1 | THERAPEUTIC COMPOSITIONS FOR WOUND TREATMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| WO-2023201345-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | GREGG JOHN M H (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023137320-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230201167-A1 | ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOF | GREGG JOHN M H (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4110330-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20130029030-A1 | METHOD FOR PROMOTION OF HEMOSTASIS AND/OR WOUND HEALING | Ferrosan Medical Devices A/S (DK) | 2013-01-31 | — | — | US | disclosed |
| EP-2259803-B1 | DEVICE FOR PROMOTION OF HEMOSTASIS AND/OR WOUND HEALING | FERROSAN MEDICAL DEVICES AS (DK) | 2012-09-05 | — | — | EP | disclosed |
| US-20110256232-A1 | ANTIMICROBIAL COMPOSITION FROM COPEPODS | NOFIMA INGREDIENS (NO) | 2011-10-20 | — | — | US | disclosed |
| US-20110212090-A1 | Combinatorial Analysis and Repair | DAKO DENMARK A/S | 2011-09-01 | — | — | US | disclosed |
| EP-2346516-A2 | ANTIMICROBIAL COMPOSITION FROM COPEPODS | Nofima Ingrediens (NO) | 2011-07-27 | — | — | EP | disclosed |
| US-20110021964-A1 | Device for Promotion of Hemostasis and/or Wound Healing | Ferrosan Medical Devices A/S (DK) | 2011-01-27 | — | — | US | disclosed |
| EP-2259803-A2 | DEVICE FOR PROMOTION OF HEMOSTASIS AND/OR WOUND HEALING | Ferrosan Medical Devices A/S (DK) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010049454-A2 | ANTIMICROBIAL COMPOSITION FROM COPEPODS | NOFIMA INGREDIENS (NO) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010009735-A2 | COMBINATORIAL ANALYSIS AND REPAIR | DAKO DENMARK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009109194-A2 | DEVICE FOR PROMOTION OF HEMOSTASIS AND/OR WOUND HEALING | FERROSAN A/S (DK) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | ACE2, ACE, SARS1 | TOP1 933/4885ESR1 4530/4885ESR2 3243/4885 |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | TOP1 45/4885ESR1 2305/4885ESR2 3906/4885 |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | ACE2, ACE, MAVS | TOP1 1753/4885ESR1 4646/4885ESR2 3048/4885 |
| US-20230201167-A1 | ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOF | ACE2, ACE, MAVS | TOP1 1753/4885ESR1 4646/4885ESR2 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.